The short answer
On 21 May 2026 the CHMP adopted a positive opinion recommending an extension to Wegovy's marketing authorisation, adding tablets for oral use in four strengths, 1.5 mg, 4 mg, 9 mg and 25 mg. It would be the first GLP-1 receptor agonist for weight management developed for oral use.
Key facts
- Opinion adopted
- 21 May 2026
- Meeting
- CHMP, 18-21 May 2026
- Type
- Variation (new pharmaceutical form and route)
- Strengths
- 1.5 mg, 4 mg, 9 mg, 25 mg
- Existing form
- Weekly subcutaneous injection
- Status
- Opinion, not yet a decision
What a CHMP positive opinion is
A recommendation from the EMA's scientific committee, not the authorisation itself. The European Commission takes the legal decision afterwards, and it follows the opinion in the great majority of cases. Reporting a positive opinion as an approval is a common and slightly premature conflation.
What specifically was recommended
A variation adding a new pharmaceutical form with a new route of administration. Tablets for oral use, in four strengths: 1.5 mg, 4 mg, 9 mg and 25 mg. This extends an existing authorisation rather than creating a new one, since Wegovy is already authorised as a weekly subcutaneous injection.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
A distinction worth getting right
Secondary coverage has described this opinion as covering oral Wegovy and a 7.2 mg pen together. It does not. The recommendation concerns oral tablets in the four strengths listed. The 7.2 mg figure belongs to STEP UP, a separate phase 3b trial of a higher-dose once-weekly injectable, a different formulation, a different route and a different regulatory question.
Why an oral peptide is difficult
Peptides are digested. Oral semaglutide addresses this with the absorption enhancer SNAC and strict administration conditions, and even then absorption is a small and variable fraction of the dose. That is why the tablet strengths are so much larger than the injectable dose. The numbers are not comparable across routes.
How this sits against the small molecules
Orforglipron and aleniglipron avoid the problem by not being peptides at all, so they need no absorption enhancer and no administration conditions. Oral semaglutide keeps peptide pharmacology and solves delivery by formulation. Both routes to an oral GLP-1 are now real, and they involve entirely different trade-offs.
What this does not concern
Research material. This is a regulatory step for a licensed medicine assessed by the EMA. Nothing supplied here is semaglutide in any form, and no research compound is an alternative to a prescribed weight-management medicine.
Frequently asked questions
Which strengths were recommended?
Tablets for oral use in 1.5 mg, 4 mg, 9 mg and 25 mg.
Does the opinion include a 7.2 mg pen?
No. That figure belongs to STEP UP, a separate trial of a higher-dose once-weekly injectable, a different route and a different regulatory question.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- MARITIME: Where the Monthly Compound Is Being TestedMaridebart cafraglutide's Phase 3 programme spans obesity, sleep apnoea and heart failure - including a 5,056-participant cardiology trial.
- Reading a Programme From Its Trial RegistrationsOne trial was withdrawn with zero enrolment; three others are completed, active or recruiting. Withdrawn and terminated mean different things.
- What the Systematic Reviews Say About Children and AdolescentsTwo 2025 systematic reviews assessed GLP-1 agonists in children and adolescents. What review-level evidence establishes, and what is still missing.
- What the Human Studies Have FoundA BMJ Scandinavian cohort, a JAMA Network Open analysis of 13 cancers, and a 2025 meta-analysis of randomised trials. What each design can support.
- Semaglutide in Obesity-Related Heart FailureKosiborod 2023 in NEJM and a pooled Lancet analysis in 2024. Randomised evidence in HFpEF, which is a stronger design than the observational work.